Extracellular vesicles (CARMEV) and mitochondria (MOT™) for prevention of kidney and heart failure
| Reference number | |
| Coordinator | Uppsala universitet - Uppsala universitet Inst f kirurgiska vetenskaper |
| Funding from Vinnova | SEK 1 000 000 |
| Project duration | November 2024 - November 2025 |
| Status | Ongoing |
| Venture | Preparation projects for international application within health |
| Call | Towards deeper collaboration with UK and USA partners within Health and Life Science |
Purpose and goal
Heart failure and renal failure after myocardial infarction is a common problem and is due to the fact that the acute treatment with balloon dilatation and stenting does not prevent the ischemia-reperfusion injury in the heart and kidneys. In this project, we will evaluate the effect of immunomodulating extracellular vesicles (CARMEV) and mitochondria to protect the heart and kidneys in everything from small animals to large animal models with the aim to produce a new optimal combination.
Expected effects and result
Successful implementation of this project will allow to define the optimal dose/ ratio of CARMEV and mitochondria to be used both for optimal storage and distribution, but also for optimal protection of the heart and kidney functions after ischemia-reperfusion injury. All the animal models used in this study are in line with the demands of product development and will be the basis for defining of a new ATMP product to be used for clinical trials.
Planned approach and implementation
In this collaboration, we will first identify the optimal dose combination of CARMEV and mitochondria required to protect mitochondrial function during storage and transport. In the next step, we will study the optimal dose combination of CARMEV and mitochondria that reduce scarring after heart attack in mice, where we will use a completely new imaging method. In the last step, we will study the effect of CARMEV and mitochondria on preventing acute kidney failure in a large animal model.